1. Home
  2. ASLE vs ALLO Comparison

ASLE vs ALLO Comparison

Compare ASLE & ALLO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ASLE
  • ALLO
  • Stock Information
  • Founded
  • ASLE 2008
  • ALLO 2017
  • Country
  • ASLE United States
  • ALLO United States
  • Employees
  • ASLE N/A
  • ALLO N/A
  • Industry
  • ASLE Industrial Specialties
  • ALLO Biotechnology: Biological Products (No Diagnostic Substances)
  • Sector
  • ASLE Consumer Discretionary
  • ALLO Health Care
  • Exchange
  • ASLE Nasdaq
  • ALLO Nasdaq
  • Market Cap
  • ASLE 271.8M
  • ALLO 277.8M
  • IPO Year
  • ASLE N/A
  • ALLO 2018
  • Fundamental
  • Price
  • ASLE $5.82
  • ALLO $1.23
  • Analyst Decision
  • ASLE Strong Buy
  • ALLO Strong Buy
  • Analyst Count
  • ASLE 3
  • ALLO 9
  • Target Price
  • ASLE $8.67
  • ALLO $8.44
  • AVG Volume (30 Days)
  • ASLE 299.6K
  • ALLO 2.4M
  • Earning Date
  • ASLE 08-06-2025
  • ALLO 08-06-2025
  • Dividend Yield
  • ASLE N/A
  • ALLO N/A
  • EPS Growth
  • ASLE N/A
  • ALLO N/A
  • EPS
  • ASLE N/A
  • ALLO N/A
  • Revenue
  • ASLE $320,302,000.00
  • ALLO N/A
  • Revenue This Year
  • ASLE $2.54
  • ALLO N/A
  • Revenue Next Year
  • ASLE $16.24
  • ALLO $199.63
  • P/E Ratio
  • ASLE N/A
  • ALLO N/A
  • Revenue Growth
  • ASLE N/A
  • ALLO N/A
  • 52 Week Low
  • ASLE $4.53
  • ALLO $0.86
  • 52 Week High
  • ASLE $8.76
  • ALLO $3.78
  • Technical
  • Relative Strength Index (RSI)
  • ASLE 41.27
  • ALLO 44.00
  • Support Level
  • ASLE $5.66
  • ALLO $1.27
  • Resistance Level
  • ASLE $6.12
  • ALLO $1.51
  • Average True Range (ATR)
  • ASLE 0.20
  • ALLO 0.11
  • MACD
  • ASLE 0.02
  • ALLO -0.00
  • Stochastic Oscillator
  • ASLE 35.16
  • ALLO 17.65

About ASLE AerSale Corporation

AerSale Corp is an integrated, diversified leader in aviation aftermarket products and services. It specializes in the sale, lease, and exchange of used aircraft, engines, and components, in addition to providing a broad range of maintenance, repair, and overhaul, and engineering services for commercial aircraft and components. The company operating segment includes Asset Management Solutions and TechOps. It generates maximum revenue from the Asset Management Solutions segment.

About ALLO Allogene Therapeutics Inc.

Allogene Therapeutics Inc is a clinical-stage biotech firm specializing in immuno-oncology, focusing on the development of genetically engineered allogeneic T-cell products for cancer and autoimmune diseases. Their pipeline includes off-the-shelf T-cell candidates designed to target cancer cells or autoreactive cells in autoimmune disorders. Notably, their allogeneic approach, derived from healthy donors, allows for broader patient eligibility and scalability. With a vision to redefine CAR T therapy, the company concentrates on core programs targeting lymphoma, leukemia, autoimmune diseases, and solid tumors. Revenue, generated from collaborations and licensing agreements, supports their research and development efforts.

Share on Social Networks: